Analgesic Efficacy of Ultrasound-guided Transverse-abdominal Plain Blockade in Urological Surgery

Ultrasound-guided Analgesic Transverse Abdominal Plain Blockade in the Multimodal Pain Management for Laparoscopic Urological Surgery. Analgesic Efficacy Assessment.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01501565

Enrollment

141

Registered

2011-12-29

Start date

2011-12-31

Completion date

2012-11-30

Last updated

2012-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Postoperative pain, Transverse abdominal blockade, Efficacy, Safety, Urology

Brief summary

The purpose of this study is to compare pain level (according to numerical score)at 4, 8, 12 and 24 postoperative hours between patients under transverse abdominal plain blockade (TAP) and patients under conventional analgesia. Also the opioid consumption is assessed.

Interventions

PROCEDUREPostoperative transverse abdominal plain (TAP) blockade

Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* \> 18 yrs. * Patients undergo laparoscopic urologic surgery * Physical status ASA \< 3 * Surgical procedure without complications * Signed informed consent

Exclusion criteria

* Allergy to bupivacaine chlorhydrate * Patients with chronic pain treatment * Alcoholism * Decompensated hepatic disease * Coagulation disorders * BMI \> 35 * Patient involved in another clinical trial

Design outcomes

Primary

Measure	Time frame	Description
Pain level	Change in pain from admittance to 24 hours postoperatively	Pain is assessed by numerical scale (0 to 10) where 0 is no pain and 10 is the most intense pain possible. Pain will be assessed at 4, 6 , 8, 12 and 24 hours.

Secondary

Measure	Time frame	Description
Analgesic consumption as a rescue therapy	within 24 postoperative hours	Analgesic consumption: morphine in miligrams.
Incidence of postoperative nausea and vomiting (PONV) related to therapy	within 24 postoperative hours	Assessment of PONV incidence and antiemetic drugs consumption.
Incidence of urethral/bladder spasm	within 24 postoperative hours	Pain due to bladder catheter.
Assessment of oral intake tolerance	within 24 postoperative hours	Assessment at 6 postoperative hours for liquids, and solid food at 24 postoperative hours.
Patient satisfaction	within 24 postoperative hours	Assessed by ordinal scale: Very pleased/Pleased/little pleased/little unpleased/unpleased/very unpleased

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026